Skip to main content
Avicanna Inc. logo

Avicanna Inc. — Investor Relations & Filings

Ticker · AVCN ISIN · CA05368K1003 LEI · 254900AUQ4URGWO3FN90 TSX Manufacturing
Open in API
Filings indexed 484 across all filing types
Latest filing 2026-05-14 Earnings Release
Country CA Canada
Listing TSX AVCN

About Avicanna Inc.

https://www.avicanna.com/

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based, cannabinoid-based products for the global medical and pharmaceutical markets. The company operates through four commercial pillars: Medical Cannabis Products (RHO Phyto™), a Medical Cannabis Care Platform (MyMedi.ca), a Pharmaceutical Pipeline, and Active Pharmaceutical Ingredients (Aureus Santa Marta™). Avicanna leverages an industry-leading scientific platform, including R&D collaborations with academic institutions and a robust IP portfolio, resulting in over 50 proprietary commercialized SKUs.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Earnings Release Classification · 91% confidence The document is a press release announcing Q1 2026 financial results, including revenue, gross profit, EBITDA metrics and operational highlights. It provides summary financial data and management commentary typical of an initial quarterly earnings announcement rather than the full interim report. Therefore, it is classified as an Earnings Release (ER). Q1 2026
2026-05-14 English
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 84% confidence The document is a Form 52-109F2 “Certification of Interim Filings” signed by the CEO, providing attestation on the completeness and fair presentation of interim financial statements and MD&A. It does not contain the actual interim financial statements or substantive financial data, but is an officer certification letter under National Instrument 52-109. Per the Certification Rule, such letters are classified as Regulatory Filings (RNS), not as the interim report itself.
2026-05-13 English
Interim MD&A - English.pdf
Management Reports Classification · 88% confidence The document is titled “Management’s Discussion and Analysis” (MD&A) for the quarter ended March 31, 2026. It provides management’s detailed explanation of financial results, business trends, outlook, and substantive financial metrics for Q1 2026 but does not include full financial statements. It is therefore a standalone MD&A filing rather than a full interim report or earnings release. This corresponds to the “Management Reports” category (MDA).
2026-05-13 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled "Consolidated Interim Financial Statements" for the three months ended March 31, 2026 and 2025 and includes full unaudited consolidated financial statements (balance sheet, income statement, cash flows, equity changes) and detailed notes. This matches the definition of an Interim / Quarterly Report (IR), as it provides substantive financial data for a period shorter than a full fiscal year. Q1 2026
2026-05-13 English
Report of voting results.pdf
Regulatory Filings
2026-05-08 English
News release - English.pdf
Regulatory Filings
2026-05-08 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.